https://www.selleckchem.com/
1% (1/9). All patients were alive at the time of this analysis and two patients had disease progression. After a median follow-up of 17 months (range 5-44 months), the median event-free survival and postoperative survival was 14 months (range 2-44 months) and 17 months (range 5-44 months) respectively. CONCLUSIONS Salvage surgery may be a feasible and promising therapeutic option for tumor recurrence or residual tumor in advanced NSCLC in selective patients after targeted therapy. © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group an
إعجاب
علق
شارك
